Search results for "Burden of disease"

showing 10 items of 68 documents

2018

0301 basic medicineBurden of diseaseCancer Researchbusiness.industryCancermedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineYears of potential life lostOncologyCancer incidence030220 oncology & carcinogenesismedicinebusinessDemographyJAMA Oncology
researchProduct

Estimating Global Burden of Disease due to congenital anomaly: an analysis of European data

2017

ObjectiveTo validate the estimates of Global Burden of Disease (GBD) due to congenital anomaly for Europe by comparing infant mortality data collected by EUROCAT registries with the WHO Mortality Database, and by assessing the significance of stillbirths and terminations of pregnancy for fetal anomaly (TOPFA) in the interpretation of infant mortality statistics.Design, setting and outcome measuresEUROCAT is a network of congenital anomaly registries collecting data on live births, fetal deaths from 20 weeks’ gestation and TOPFA. Data from 29 registries in 19 countries were analysed for 2005–2009, and infant mortality (deaths of live births at age <1 year) compared with the WHO Mortality …

0301 basic medicineMalePediatrics030105 genetics & heredityInfant DeathGlobal Burden of Disease0302 clinical medicineCongenital anomaly ; DALY ; Global Burden of Disease ; YLL ; mortality.PregnancyPrenatal DiagnosisYLLEpidemiologyInfant MortalityPrevalenceMedicineEPIDEMIOLOGY030212 general & internal medicineRegistries1506DOWN-SYNDROMEPOPULATIONeducation.field_of_studyDALYAnomaly (natural sciences)Pregnancy OutcomeObstetrics and GynecologyGestational ageGeneral MedicineStillbirthUPDATED SYSTEMATIC ANALYSISPREVALENCEEuropeFetal Mortality/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemaleOriginal ArticleCHILD-MORTALITYAdultCOUNTRIESmedicine.medical_specialtyPopulationGestational AgeCongenital Abnormalities03 medical and health sciencesSDG 3 - Good Health and Well-beingJournal ArticleHumansCongenital anomalyAbortion Induced/statistics & numerical data; Adult; Congenital Abnormalities/diagnosis; Congenital Abnormalities/epidemiology; Europe/epidemiology; Female; Fetal Death/prevention & control; Fetal Mortality; Gestational Age; Global Burden of Disease/methods; Global Burden of Disease/statistics & numerical data; Humans; Infant; Infant Death/prevention & control; Infant Mortality; Infant Newborn; Male; Pregnancy; Pregnancy Outcome/epidemiology; Prenatal Diagnosis/methods; Prenatal Diagnosis/statistics & numerical data; Prevalence; Registries/statistics & numerical data; Stillbirth/epidemiology; Congenital anomaly; DALY; Global Burden of Disease; YLL; mortalityeducationFetal DeathPregnancybusiness.industryInfant NewbornInfantAbortion InducedNATIONAL CAUSESmedicine.diseasemortalityTRENDSInfant mortalityChild mortalityYears of potential life lostPediatrics Perinatology and Child HealthbusinessPRIMARY PREVENTIONDemography
researchProduct

International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia

2019

Objective: Streptococcus pneumoniae is the most frequent bacterial pathogen isolated in subjects with Community-acquired pneumonia (CAP) worldwide. Limited data are available regarding the current global burden and risk factors associated with drug-resistant Streptococcus pneumoniae (DRSP) in CAP subjects. We assessed the multinational prevalence and risk factors for DRSP-CAP in a multinational point-prevalence study. Design: The prevalence of DRSP-CAP was assessed by identification of DRSP in blood or respiratory samples among adults hospitalized with CAP in 54 countries. Prevalence and risk factors were compared among subjects that had microbiological testing and antibiotic susceptibility…

0301 basic medicineMaleStreptococcus pneumoniaantibiotic resistanceInternationalitysputum examinationbronchiectasisvery elderlyAntibioticsPrevalenceDrug resistancemedicine.disease_causeLogistic regressionGlobal HealthCommunity-Acquired Infections/epidemiologylung lavage0302 clinical medicineCommunity-acquired pneumoniaCost of IllnessRisk FactorsPrevalencedrug resistant Streptococcus pneumoniae pneumonia030212 general & internal medicineMicrobial drug resistantAged 80 and overadultinternational cooperationdrug effectMiddle Agedinfluenza vaccinationAnti-Bacterial Agentsantiinfective agentEuropeCommunity-Acquired InfectionsHospitalizationGlobal burden of diseaseStreptococcus pneumoniaeInfectious Diseasesrisk factorbacterium identificationFemalecommunity acquired infectioninfluenzaliver diseasepneumococcal vaccinationPneumococcal infectionhospitalizationmedicine.drugMicrobiology (medical)medicine.medical_specialtyAsiamedicine.drug_class030106 microbiologySettore MED/10 - Malattie Dell'Apparato RespiratorioArticleAnti-Bacterial Agents/pharmacology03 medical and health sciencesInternal medicineStreptococcus pneumoniaeDrug Resistance BacterialPneumonia Pneumococcal/epidemiologymedicineHumanscontrolled studyhumantetracyclineHospitalization/statistics & numerical dataAgedlevofloxacinnonhumanbusiness.industrydisease associationmicrobiologycommunity acquired pneumoniamacrolidePneumoniaasthmaSouth AmericaPneumonia Pneumococcalvaccinationmedicine.diseasemajor clinical studyantibiotic sensitivitypenicillin derivativePenicillinStreptococcus pneumoniae/drug effectsPneumoniablood examinationAfricaNorth Americamicrobiological examinationbusinessGlobal burden of disease; Microbial drug resistant; Pneumococcal infection; Pneumonia
researchProduct

Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015

2016

BACKGROUND: In transitioning from the Millennium Development Goal to the Sustainable Development Goal era, it is imperative to comprehensively assess progress toward reducing maternal mortality to identify areas of success, remaining challenges, and frame policy discussions. We aimed to quantify maternal mortality throughout the world by underlying cause and age from 1990 to 2015.METHODS: We estimated maternal mortality at the global, regional, and national levels from 1990 to 2015 for ages 10-54 years by systematically compiling and processing all available data sources from 186 of 195 countries and territories, 11 of which were analysed at the subnational level. We quantified eight underl…

0301 basic medicinePediatricsNutrition and DiseaseMILLENNIUM DEVELOPMENT GOALSSUSTAINABLE DEVELOPMENT GOALSANTENATAL CAREGlobal Health0302 clinical medicineVoeding en Ziekte11. SustainabilityGlobal healthHQHealthcare FinancingEMERGENCY OBSTETRIC CARE030212 general & internal medicineCooperative Behavior10. No inequalityReproductive healthMedicine(all)education.field_of_study030219 obstetrics & reproductive medicineMedicine (all)1. No povertyObstetrics and GynecologyPublic Health Global Health Social Medicine and EpidemiologyPrenatal CareGeneral Medicine11 Medical And Health SciencesLOW-RESOURCE SETTINGS3142 Public health care science environmental and occupational healthFamily Planning Service3. Good healthGBD 2015 Maternal Mortality CollaboratorsGovernment ProgramsMaternal MortalityReproductive HealthFamily Planning ServicesMaternal deathHEALTHLife Sciences & BiomedicineHumanCOUNTRIESmedicine.medical_specialtyPopulation610Prenatal careArticle03 medical and health sciencesMedicine General & InternalSDG 3 - Good Health and Well-beingCASH TRANSFER PROGRAMEnvironmental healthGeneral & Internal Medicineparasitic diseasesmedicineLife ScienceQUALITYHumansGlobal Burden of Disease StudyeducationVLAGScience & TechnologyMedical Assistancebusiness.industryKlinisk medicinParturitionObstetric transitionmedicine.diseaseQPInfant mortalityFolkhälsovetenskap global hälsa socialmedicin och epidemiologiStandardized mortality ratio030104 developmental biologyRISK-FACTORSRGClinical MedicinebusinessRA
researchProduct

Impact of COVID-19 on global HCV elimination efforts.

2021

Background & Aims COVID-19 has placed significant strain on national healthcare systems at a critical moment in the context of hepatitis elimination. Mathematical models can be used to evaluate the possible impact of programmatic delays on hepatitis disease burden. The objective of this analysis was to evaluate the incremental change in hepatitis C liver-related deaths and liver cancer, following a 3-month, 6-month, or 1-year hiatus in hepatitis elimination program progress. Methods Previously developed models were adapted for 110 countries to include a status quo or “no delay” scenario and a “1-year delay” scenario assuming significant disruption in interventions (screening, diagnosis and …

0301 basic medicinePsychological interventioncoronavirusUMIC upper-middle income countriesGlobal HealthUI uncertainty intervalHIC high income countries0302 clinical medicineCost of IllnessLIC low income countriesMedicineUSA United States of AmericaLetter to the EditorMathematical modellingPWID people who inject drugsLiver DiseaseLiver DiseasesVaccinationmathematical modelingGBD Global Burden of DiseaseHepatitis CSVR sustained virologic responseEuropeHCV hepatitis C virusHepatocellular carcinomaHCVGHSS Global Health Sector StrategyRNA Viral030211 gastroenterology & hepatologyAMR region of the AmericasLiver cancerViral hepatitisHumanCarcinoma HepatocellularCoronavirus disease 2019 (COVID-19)EMR Eastern Mediterranean regionViral hepatitis eliminationviral hepatitisContext (language use)World Health OrganizationArticleWHO World Health OrganizationTime-to-Treatment03 medical and health scienceseliminationEnvironmental healthHumansLMIC lower-middle income countriesDisease EradicationDisease burdenHepatitisHepatologySARS-CoV-2business.industryWPR Western Pacific regionCOVID-19Models Theoreticalmedicine.diseaseCost of Illne030104 developmental biologySpainHCC hepatocellular carcinomabusinessJournal of hepatology
researchProduct

Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study

2021

Background. High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units across sub-Saharan Africa. Methods. In this modelling study, we developed a framework that used the geographically specific HIV prevalence data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to e…

0301 basic medicinesub-Saharan AfricaMaleHIV AntibodieEpidemiologyHIV incidencesHIV Infectionsmortality rateHIV AntibodiesModelling studyHuman immunodeficiency virus prevalence0302 clinical medicineAfrica NorthernRA0421Seroepidemiologic StudiesMedicineNorthernHIV Infection030212 general & internal medicineYoung adult10. No inequalityuncertaintyMozambique11 Medical and Health SciencesHIV mortalityMortality rateIncidence (epidemiology)Incidence1. No povertyHiv incidencearticleMauritaniaHuman immunodeficiency virus infected patientArticlestrackingMiddle Agedhealth care planning3. Good healthPeer reviewLesothoAIDSInfectious DiseasesQR180A990 Medicine and Dentistry not elsewhere classifiedFemaleprenatal careanti human immunodeficiency virus agentseroepidemiologyHumanAdultAdolescentAnti-HIV AgentsImmunologyantiretroviral therapyUnit (housing)03 medical and health sciencesYoung AdultbloodHuman immunodeficiency virus infectionVirologySeroprevalenceHumanshumanDeveloping CountriesEstimationAcquired Immunodeficiency SyndromeSubnational mappingsbusiness.industrySeroepidemiologic StudieHIVAnti-HIV AgentPREVENTION030112 virologymortalitymonitoring3121 General medicine internal medicine and other clinical medicineHuman immunodeficiency virus antibodyAfricabusinessHIV incidence ; HIV mortality ; Subnational mapping ; Sub-Saharan Africa ; Local burden of disease ; Public healthDemography
researchProduct

Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease St…

2022

Correction to Lancet Gastroenterol Hepatol 2022; 7: 627-47. Lancet Gastroenterol Hepatol. 2022 Aug;7(8):704. doi: 10.1016/S2468-1253(22)00210-2. PMID: 35809605. Background: Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Methods: Estimates of incidenc…

AdultMED/42 - IGIENE GENERALE E APPLICATAIMPACTcolorectal cancerColorectal NeoplasmGBD 2019 Colorectal Cancer CollaboratorsHEREDITARYGlobal Burden of DiseaseCancer screeningDISPARITIESSDG 3 - Good Health and Well-beingCancer treatment strategiesRisk FactorsQuality-Adjusted Life YearCOLONGlobal studiesDALY GBD colorectal cancerrisk factorsHumansGlobal Burden of Disease StudyEarly Detection of CancerHepatologyMORTALITYGastroenterologyCancer incidence ratesMiddle AgedCancer burdenSURVIVAL/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSEXGENDERQuality-Adjusted Life YearsColorectal NeoplasmsHumanThe Lancet Gastroenterology & Hepatology
researchProduct

Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study …

2022

Background: The health risks associated with moderate alcohol consumption continue to be debated. Small amounts of alcohol might lower the risk of some health outcomes but increase the risk of others, suggesting that the overall risk depends, in part, on background disease rates, which vary by region, age, sex, and year. Methods: For this analysis, we constructed burden-weighted dose-response relative risk curves across 22 health outcomes to estimate the theoretical minimum risk exposure level (TMREL) and non-drinker equivalence (NDE), the consumption level at which the health risk is equivalent to that of a non-drinker, using disease rates from the Global Burden of Diseases, Injuries, and …

AdultMaleAlcohol DrinkingCONTROL POLICIESadult; Alcohol Drinking; Child Preschool; Female; Geography; Global Burden of Disease; Global Health; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Risk FactorsNDASALL-CAUSEGUIDELINESGlobal HealthGBD 2020 Alcohol CollaboratorsGlobal Burden of DiseaseCOST-EFFECTIVENESSMedicine General & InternalDRINKINGSDG 3 - Good Health and Well-beingRA0421Risk FactorsGeneral & Internal MedicineQuality-Adjusted Life YearRA0421 Public health. Hygiene. Preventive MedicineDRINKERSHumansChildPreschool11 Medical and Health SciencesMETAANALYSISMCCScience & Technologyglobal burden of diseaseGeographyRisk FactoradultGeneral MedicineMiddle AgedCANCERalcohol drinkingACChild Preschool3121 General medicine internal medicine and other clinical medicineFemaleQuality-Adjusted Life YearsREDUCED MORTALITYLife Sciences & Biomedicinealcohol drinking; global burden of disease; adultHuman
researchProduct

Burden of disease assessment with summary measures of population health for the Region of Valencia, Spain: a population-based study

2011

Abstract Background and objective An important input to decision-making and health planning is a consistent and comparative description of the population health status. The purpose of this study was to describe the burden of disease in the Region of Valencia (Spain). Material and methods Disability-adjusted life years (DALYs) were calculated and divided into years of life lost (YLLs) and years lived with disability (YLDs). Using death registry data and Valencian population estimates in 2008, we calculated the number of deaths and YLLs. YLDs were based on age- and sex-specific data for countries of the EURO-A subregional level (which includes the Region of Valencia) from the Global Burden of…

AdultMaleBurden of diseaseAdolescentSense organHealth StatusPopulationPopulation healthValencianYoung AdultAge DistributionLife ExpectancyCost of IllnessCause of DeathHumansMedicineDisabled PersonsSex DistributionChildeducationDiagnosis-Related GroupsDisease burdenDepression (differential diagnoses)AgedAged 80 and overeducation.field_of_studybusiness.industryInfant NewbornInfantGeneral MedicineMiddle Agedlanguage.human_languageYears of potential life lostSpainChild PreschoolChronic DiseaselanguageFemalebusinessDemographyMedicina Clínica
researchProduct

Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study…

2022

Funding: Bill & Melinda Gates Foundation. Background: The global burden of lower respiratory infections (LRIs) and corresponding risk factors in children older than 5 years and adults has not been studied as comprehensively as it has been in children younger than 5 years. We assessed the burden and trends of LRIs and risk factors across all age groups by sex, for 204 countries and territories.  Methods: In this analysis of data for the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, we used clinician-diagnosed pneumonia or bronchiolitis as our case definition for LRIs. We included International Classification of Diseases 9th edition codes 079.6, 466–469, 470.0, 480–4…

AdultMaleGlobal HealthTimeGlobal Burden of DiseaseSDG 3 - Good Health and Well-beingRisk FactorsRA0421RA0421 Public health. Hygiene. Preventive MedicineHumansAmbient air-qualityChildRespiratory Tract InfectionsAgedAged 80 and overMCCSex CharacteristicsMalnutritionPyridinolcarbamateBayes Theorem3rd-DAS3142 Public health care science environmental and occupational healthInfectious Diseases3121 General medicine internal medicine and other clinical medicineChild PreschoolFemaleParticulate MatterQuality-Adjusted Life YearsCovid-19LRI
researchProduct